Overview

HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss

Status:
Withdrawn
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Up to half of all cases of recurrent pregnancy loss are unexplained (uRPL). Evidence points towards endometriosis and progesterone resistance as an underlying cause of uRPL. Previous non-RCT studies have suggested the luteal hCG provides a useful treatment for uRPL. We propose performing a randomized controlled trial to compare mid-luteal hCG with oral progesterone to prevent early pregnancy losses. the endpoint will be ongoing pregnancy and live birth rates. Equal numbers of patients will be randomized to each group.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Progesterone